Logo image of STAA

STAAR SURGICAL CO (STAA) Stock Fundamental Analysis

NASDAQ:STAA - Nasdaq - US8523123052 - Common Stock - Currency: USD

16.34  -0.51 (-3.03%)

After market: 16.34 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to STAA. STAA was compared to 187 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for STAA as it has an excellent financial health rating, but there are worries on the profitability. STAA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

STAA had negative earnings in the past year.
In the past year STAA has reported a negative cash flow from operations.
STAA had positive earnings in 4 of the past 5 years.
In the past 5 years STAA always reported a positive cash flow from operatings.
STAA Yearly Net Income VS EBIT VS OCF VS FCFSTAA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

With a Return On Assets value of -15.54%, STAA perfoms like the industry average, outperforming 54.01% of the companies in the same industry.
STAA's Return On Equity of -20.31% is fine compared to the rest of the industry. STAA outperforms 60.96% of its industry peers.
Industry RankSector Rank
ROA -15.54%
ROE -20.31%
ROIC N/A
ROA(3y)3.25%
ROA(5y)3.83%
ROE(3y)4.04%
ROE(5y)4.92%
ROIC(3y)N/A
ROIC(5y)N/A
STAA Yearly ROA, ROE, ROICSTAA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

STAA's Gross Margin of 74.00% is amongst the best of the industry. STAA outperforms 86.10% of its industry peers.
STAA's Gross Margin has been stable in the last couple of years.
STAA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.47%
STAA Yearly Profit, Operating, Gross MarginsSTAA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

STAA does not have a ROIC to compare to the WACC, probably because it is not profitable.
STAA has more shares outstanding than it did 1 year ago.
STAA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, STAA has an improved debt to assets ratio.
STAA Yearly Shares OutstandingSTAA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
STAA Yearly Total Debt VS Total AssetsSTAA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 5.11 indicates that STAA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.11, STAA is in the better half of the industry, outperforming 77.01% of the companies in the same industry.
STAA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.11
ROIC/WACCN/A
WACC9.03%
STAA Yearly LT Debt VS Equity VS FCFSTAA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

STAA has a Current Ratio of 4.78. This indicates that STAA is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.78, STAA is doing good in the industry, outperforming 72.19% of the companies in the same industry.
STAA has a Quick Ratio of 4.07. This indicates that STAA is financially healthy and has no problem in meeting its short term obligations.
STAA has a Quick ratio of 4.07. This is in the better half of the industry: STAA outperforms 74.33% of its industry peers.
Industry RankSector Rank
Current Ratio 4.78
Quick Ratio 4.07
STAA Yearly Current Assets VS Current LiabilitesSTAA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for STAA have decreased strongly by -145.31% in the last year.
The Earnings Per Share has been growing slightly by 7.49% on average over the past years.
Looking at the last year, STAA shows a very negative growth in Revenue. The Revenue has decreased by -14.44% in the last year.
Measured over the past years, STAA shows a quite strong growth in Revenue. The Revenue has been growing by 15.88% on average per year.
EPS 1Y (TTM)-145.31%
EPS 3Y-12.35%
EPS 5Y7.49%
EPS Q2Q%-688.89%
Revenue 1Y (TTM)-14.44%
Revenue growth 3Y10.84%
Revenue growth 5Y15.88%
Sales Q2Q%-44.94%

3.2 Future

Based on estimates for the next years, STAA will show a very strong growth in Earnings Per Share. The EPS will grow by 22.71% on average per year.
The Revenue is expected to grow by 5.19% on average over the next years.
EPS Next Y-584.9%
EPS Next 2Y-81.01%
EPS Next 3Y-33.46%
EPS Next 5Y22.71%
Revenue Next Year-25.31%
Revenue Next 2Y-1.71%
Revenue Next 3Y1.07%
Revenue Next 5Y5.19%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
STAA Yearly Revenue VS EstimatesSTAA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
STAA Yearly EPS VS EstimatesSTAA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 1 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STAA. In the last year negative earnings were reported.
STAA is valuated quite expensively with a Price/Forward Earnings ratio of 1372.72.
64.17% of the companies in the same industry are more expensive than STAA, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.19. STAA is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 1372.72
STAA Price Earnings VS Forward Price EarningsSTAA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 500 1K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STAA Per share dataSTAA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

STAA's earnings are expected to decrease with -33.46% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-81.01%
EPS Next 3Y-33.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for STAA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STAAR SURGICAL CO

NASDAQ:STAA (6/20/2025, 8:00:00 PM)

After market: 16.34 0 (0%)

16.34

-0.51 (-3.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners109.32%
Inst Owner Change8.9%
Ins Owners0.38%
Ins Owner Change18.39%
Market Cap809.32M
Analysts71
Price Target22.59 (38.25%)
Short Float %11.35%
Short Ratio6.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1693.07%
Min EPS beat(2)-3398.76%
Max EPS beat(2)12.63%
EPS beat(4)3
Avg EPS beat(4)-804.54%
Min EPS beat(4)-3398.76%
Max EPS beat(4)120.44%
EPS beat(8)5
Avg EPS beat(8)-392.44%
EPS beat(12)9
Avg EPS beat(12)-233.83%
EPS beat(16)12
Avg EPS beat(16)-144.65%
Revenue beat(2)1
Avg Revenue beat(2)-17.15%
Min Revenue beat(2)-37.91%
Max Revenue beat(2)3.61%
Revenue beat(4)2
Avg Revenue beat(4)-8.1%
Min Revenue beat(4)-37.91%
Max Revenue beat(4)3.61%
Revenue beat(8)3
Avg Revenue beat(8)-4.68%
Revenue beat(12)4
Avg Revenue beat(12)-2.78%
Revenue beat(16)6
Avg Revenue beat(16)-1.16%
PT rev (1m)2.53%
PT rev (3m)0.39%
EPS NQ rev (1m)1.91%
EPS NQ rev (3m)-14.82%
EPS NY rev (1m)4.2%
EPS NY rev (3m)-77.58%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)-1.13%
Revenue NY rev (1m)-1.42%
Revenue NY rev (3m)-1.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1372.72
P/S 2.9
P/FCF N/A
P/OCF N/A
P/B 2.31
P/tB 2.32
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)0.01
Fwd EY0.07%
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS5.64
BVpS7.07
TBVpS7.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.54%
ROE -20.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74%
FCFM N/A
ROA(3y)3.25%
ROA(5y)3.83%
ROE(3y)4.04%
ROE(5y)4.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.47%
F-Score2
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 246.03%
Cap/Sales 7.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.78
Quick Ratio 4.07
Altman-Z 5.11
F-Score2
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)365.33%
Cap/Depr(5y)348.39%
Cap/Sales(3y)6.49%
Cap/Sales(5y)6.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-145.31%
EPS 3Y-12.35%
EPS 5Y7.49%
EPS Q2Q%-688.89%
EPS Next Y-584.9%
EPS Next 2Y-81.01%
EPS Next 3Y-33.46%
EPS Next 5Y22.71%
Revenue 1Y (TTM)-14.44%
Revenue growth 3Y10.84%
Revenue growth 5Y15.88%
Sales Q2Q%-44.94%
Revenue Next Year-25.31%
Revenue Next 2Y-1.71%
Revenue Next 3Y1.07%
Revenue Next 5Y5.19%
EBIT growth 1Y-295.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-543.45%
EBIT Next 3Y80.58%
EBIT Next 5Y67.76%
FCF growth 1Y-286.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-133.17%
OCF growth 3Y-29.01%
OCF growth 5Y-9.43%